Home›Tirzepatide›Legal status
Is Tirzepatide legal? FDA status and US regulatory standing
Current status
FDA-approved. Tirzepatide is an FDA-approved drug (status recorded ). Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. The compounding shortage exemption expired in early 2025. Current federal law generally prohibits compounded tirzepatide outside of narrow exceptions. Providers offering compounded tirzepatide should have clear documentation of their legal basis.
Primary source: www.accessdata.fda.gov
Federal legal status
FDA approval status
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). FDA declared the tirzepatide shortage resolved in December 2024.
Compounding pharmacy rules (federal)
Compounded tirzepatide was broadly permitted during the shortage period. Following FDA's shortage resolution in December 2024, 503B outsourcing facilities had until February 18, 2025, and 503A pharmacies until March 19, 2025, to wind down compounding. As of mid-2025, compounded tirzepatide is generally prohibited except for narrow clinical exceptions under a valid prescription.
Also known as
Mounjaro · Zepbound
Status history
- Tirzepatide is an FDA-approved drug. [source]
About Tirzepatide
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. It has demonstrated significant efficacy in clinical trials for both glycemic control and weight reduction, with some studies showing superior weight loss compared to semaglutide.
Frequently asked questions
- Is compounded tirzepatide legal in 2026?
- FDA declared the tirzepatide shortage resolved in December 2024. Wind-down periods ended in Q1 2025. As of mid-2025, compounded tirzepatide is generally prohibited except for documented clinical exceptions. Patients should verify the legal basis with their provider.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight with a related condition. The drugs are chemically identical.
State-level notes
Compounding and prescribing rules are administered by state pharmacy boards and vary by state. Federal FDA status (above) applies nationwide.
Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .